Head and Neck Squamous Cell Carcinomas: Biomarkers and Cellular Mechanisms towards a Precision Therapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 153

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Head & Neck Oncology & Surgery Otorhinolaryngology, Antoni van Leeuwenhoek, Nederlands Kanker Instituut, Amsterdam, The Netherlands
2. Department of Otorhinolaryngology, Head & Neck Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands
Interests: head and neck neoplasms; laryngeal neoplasms; salivary gland tumors; digital pathology; laryngology; cancer immunology; biostatistics; melanoma; cutaneous oncology; immunotherapy

Special Issue Information

Dear Colleagues,

Head and neck squamous cell carcinoma (HNSCC) is the seventh most prevalent cancer worldwide, characterized by a relatively worse prognosis and the adverse impact of treatments on patients' quality of life. Apart from surgery and radiotherapy, there are only a few available systemic treatments, primarily involving platinum-based chemotherapy or cetuximab. Immunotherapy, a novel therapeutic approach, is currently limited to palliative care for cases of recurrent, unresectable, or metastatic disease. Consequently, the exploration of new biomarkers or potentially targetable mechanisms holds significant importance. The identification of subgroups of patients that could benefit from a de-intensified treatment regimen is also of paramount importance, aimed at a precision therapy reducing the tremendous toxicity of the current treatment modalities for HNSCC.

This Special Issue of Cells is focused on the latest advances and future trends in cellular, molecular, and biomarker research in the field of head and neck cancer. This Special Issue will include both original research articles as well as up-to-date review papers.

Dr. Francesco Missale
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • biomarkers
  • prognosis
  • precision therapy
  • immunotherapy
  • translational research
  • immune contexture

Published Papers

This special issue is now open for submission.
Back to TopTop